Voyager Therapeutics Inc. (VYGR) Rating Increased to Buy at Zacks Investment Research
Voyager Therapeutics Inc. (NASDAQ:VYGR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The firm presently has a $13.00 target price on the stock. Zacks Investment Research’s price target would indicate a potential upside of 11.68% from the company’s previous close.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other analysts also recently weighed in on VYGR. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Piper Jaffray Cos. set a $37.00 target price on Voyager Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th. Finally, Stifel Nicolaus started coverage on Voyager Therapeutics in a research report on Thursday, July 14th. They issued a “buy” rating and a $33.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/voyager-therapeutics-inc-vygr-rating-increased-to-buy-at-zacks-investment-research.html
Shares of Voyager Therapeutics (NASDAQ:VYGR) traded down 0.09% during trading on Wednesday, reaching $11.63. 16,095 shares of the company were exchanged. The company’s market capitalization is $310.85 million. The firm’s 50 day moving average price is $12.86 and its 200 day moving average price is $12.72. Voyager Therapeutics has a one year low of $8.12 and a one year high of $30.54.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. Voyager Therapeutics had a negative net margin of 150.47% and a negative return on equity of 25.13%. Equities research analysts forecast that Voyager Therapeutics will post ($1.53) earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. increased its stake in shares of Voyager Therapeutics by 52.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 26,281 shares of the company’s stock valued at $289,000 after buying an additional 9,010 shares during the last quarter. State Street Corp boosted its position in Voyager Therapeutics by 147.1% in the second quarter. State Street Corp now owns 142,611 shares of the company’s stock valued at $1,565,000 after buying an additional 84,906 shares during the period. Teachers Advisors Inc. boosted its position in Voyager Therapeutics by 220.0% in the second quarter. Teachers Advisors Inc. now owns 18,757 shares of the company’s stock valued at $206,000 after buying an additional 12,895 shares during the period. TFS Capital LLC acquired a new position in Voyager Therapeutics during the second quarter valued at about $324,000. Finally, FMR LLC boosted its position in Voyager Therapeutics by 1.8% in the second quarter. FMR LLC now owns 3,973,851 shares of the company’s stock valued at $43,673,000 after buying an additional 71,503 shares during the period. Hedge funds and other institutional investors own 39.66% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.